Alemtuzumab and rheumatoid arthritis - an immunisation study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Alemtuzumab (Primary) ; DT-poliovirus vaccine; Influenza virus vaccine; Pneumococcal vaccine
- Indications Diphtheria; Influenza virus infections; Pneumococcal infections; Poliomyelitis; Rheumatoid arthritis; Tetanus
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 04 Mar 2015 Accrual to date is 55% according to United Kingdom Clinical Research Network.
- 03 Mar 2015 Status changed from recruiting to active, no longer recruiting, according to United Kingdom Clinical Research Network.